Handelsbanken Fonder AB Sells 34,965 Shares of Hologic, Inc. $HOLX

Handelsbanken Fonder AB decreased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 20.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 134,744 shares of the medical equipment provider’s stock after selling 34,965 shares during the quarter. Handelsbanken Fonder AB owned 0.06% of Hologic worth $9,094,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in HOLX. The Manufacturers Life Insurance Company increased its stake in Hologic by 294.3% in the second quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock valued at $718,223,000 after acquiring an additional 8,227,318 shares during the period. Invesco Ltd. lifted its stake in Hologic by 72.5% during the second quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after purchasing an additional 3,505,828 shares during the period. Norges Bank acquired a new stake in Hologic during the second quarter valued at approximately $180,055,000. Black Creek Investment Management Inc. grew its stake in shares of Hologic by 26.1% in the 2nd quarter. Black Creek Investment Management Inc. now owns 4,027,829 shares of the medical equipment provider’s stock valued at $262,453,000 after purchasing an additional 832,444 shares during the period. Finally, Adage Capital Partners GP L.L.C. bought a new stake in shares of Hologic in the 2nd quarter valued at approximately $48,283,000. 94.73% of the stock is owned by institutional investors.

Hologic Price Performance

Hologic stock opened at $75.36 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.32 and a current ratio of 4.04. The firm has a market cap of $16.82 billion, a P/E ratio of 31.40, a P/E/G ratio of 2.24 and a beta of 0.72. The business’s fifty day moving average is $74.95 and its two-hundred day moving average is $72.16. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $75.49.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 19.58%. The business’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.87 earnings per share. Equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HOLX has been the subject of several analyst reports. BNP Paribas Exane downgraded Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price for the company. in a research report on Friday, November 21st. Evercore lowered Hologic from an “outperform” rating to an “in-line” rating and dropped their price objective for the stock from $79.00 to $78.00 in a research note on Monday, January 5th. Morgan Stanley lifted their price objective on Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a report on Tuesday, November 11th. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. Two research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $78.42.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.